Coronavirus

Pfizer Backs Out Of Emergency Use Request For Vaccine In India; Know Why

By
OB Bureau

New Delhi: Pfizer has decided to withdraw the application for emergency use authorisation of its COVID-19 vaccine in India, the pharmaceutical major said on Friday.

Incidentally, the US company was the first firm to seek the emergency use authorisation from the Drugs Controller General of India (DCGI) for its vaccine, after it had secured similar approvals in the UK and Bahrain.

According to sources, Pfizer’s decision to withdraw its application followed a meeting with DCGI’s Subject Expert Committee earlier on Wednesday.

Confirming this, a Pfizer statement said, “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time.”

The company, however, added that it will resubmit the approval request with additional information in the near future, NDTV reported.

“Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment,” the statement said.

Behind The Scenes

Pfizer had sought authorisation for its vaccine in India late last year, but the government in January approved two much cheaper shots — one from Oxford University/AstraZeneca and another developed at home by Bharat Biotech with the Indian Council of Medical Research. Both companies had applied for approval of their vaccines after Pfizer.

Pfizer’s Take

The US company had claimed that its application was supported by data from a global study that showed an overall efficacy rate of 95 per cent with no vaccine-related, serious safety concerns, Reuters reported.

Drugs Controller Stand

However, the Central Drugs Standard Control Organisation had declined to accept Pfizer’s request for approval without a small local trial on the vaccine’s safety and immunogenicity for Indians, according to an India Today report.

Health officials said they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in Indian citizens whose genetic makeup can be different from people in Western nations.

OB Bureau

Recent Posts

New Artist To Play King Kansa Role During Dhanu Yatra In Odisha’s Bargarh

Bargarh: A new artist will be selected to play the mythological character King Kansa during…

November 22, 2024

Shah Rukh’s Daughter Suhana Khan Brutally Trolled For Vivo Ad [Watch]

Mumbai: Suhana Khan will be making her Bollywood debut with ‘King’ along with her superstar…

November 22, 2024

Badshah Comes Out In Support Of Diljit Dosanjh In Alcohol Controversy

New Delhi: After Diljit Dosanjh called out the double standards of Telangana government for banning…

November 22, 2024

World War 3 Has Begun, Says Ukraine’s Former Military Chief

New Delhi: Recent actions and counter-actions in the Russia-Ukraine conflict have pushed the world to the…

November 22, 2024

3 Arrested With Fake IPS Officers’ Uniforms, Identity Cards In Odisha’s Balangir

Balangir: Three persons were arrested and fake IPS officers’ uniforms along with fake identity cards…

November 22, 2024

‘I Want To Talk’: Twitterati Lauds Abhishek Bachchan, Say He Is Better Than Amitabh

Mumbai: Abhishek Bachchan’s highly-anticipated film ‘I Want To Talk’ released in theatres on Friday, and the…

November 22, 2024

Cash-For-Vote Row: BJP Leader’s Defamation Notice Against Rahul Gandhi, Kharge

New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…

November 22, 2024

CM Mohan Majhi Attends ‘Odisha State Day’ Celebrations At IITF In Delhi

Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…

November 22, 2024